Shaping the Future of the Business

June 2020
Forward-Looking Statements

Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning:

- the company’s mission of advancing patient-centered care and redefining what constitutes “successful treatment”;
- the company’s evolving research and development capabilities and focus, including the therapeutic areas that the company may pursue; the company’s expectations with respect to its current and future financial and operating performance, business plans or prospects, including the sufficiency of the company’s capital and liquidity position to advance its business objectives and the company’s expectations relating to potential expansion of its product portfolio, continued growth of revenue from its commercial products, and new potential elements of revenue, including royalty and manufacturing revenues for VUMERITY® and potential revenue from ALKS 3831, if approved; the company’s expectations regarding the impacts of COVID-19 on its business and the company’s ability to mitigate such impacts and maintain business continuity, including the company’s ability to protect the safety and well-being of its employees, to continue to operate its manufacturing facilities and support uninterrupted supply of its medicines and access to such medicines, to continue its ongoing clinical trials and other development activities, and to otherwise advance its business objectives; the company’s expectations concerning future regulatory activities and interactions including expected timing of the U.S. Food and Drug Administration’s (“FDA”) target Prescription Drug User Fee Act (“PDUFA”) action date for, and potential approval of, the new drug application (“NDA”) for ALKS 3831 for both the treatment of schizophrenia and the treatment of bipolar disorder, and the related advisory committee meeting with the FDA; the company’s timelines, plans and expectations concerning future development activities relating to its products and product development candidates in both neuroscience and oncology, including ongoing enrollment, activation of ex-U.S. clinical sites and other progress across the ARTISTRY clinical development program for ALKS 4230, and emerging data from such program, and preclinical research and IND-enabling activities for the company’s preclinical compounds, including the company’s HDAC inhibitor platform; the company’s expectations concerning the company’s growing commercial infrastructure and the company’s commercial activities relating to the company’s products and product candidates, including the company’s adapted commercial strategy in response to COVID-19 and preparations for the potential launch of ALKS 3831; the potential therapeutic and commercial value of the company’s marketed and development products; and the company’s expectations regarding the duration of patent protection for the company’s key development candidates and marketed products from which the company receives revenue. The company cautions that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: the potential impacts of the COVID-19 pandemic and efforts to mitigate its spread; risks related to the company’s business, results of operations and financial condition, including potential impacts on the vendors or distribution channels in the company’s supply chain, the company’s ability to continue to manufacture and market its products, the company’s ability to continue to develop its commercial activities, the conduct of the company’s clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites or monitoring of data, the healthcare systems that serve people living with opioid dependence, alcohol dependence and schizophrenia and on patient and healthcare provider access to the company’s medicines, the regulatory agencies with which the company interacts in the development, review, approval and commercialization of its medicines, the reimbursement for the company’s products, including its Medicaid rebate liability, and for services related to the use of its products, and impacts on the U.S., Irish and/or global economies more broadly; the unfavorable outcome of litigation, including so-called “Paragraph IV” litigation and other patent litigation, related to any of the company’s products may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than the company interprets it; the FDA may not agree with the company’s regulatory approval strategies or components of the company’s filings for its products, including its clinical trial designs, conduct and methodologies or the adequacy of the company’s filings or the data included in its filings to support the FDA’s requirements for approval; the company’s development activities may not be completed on time or at all; the results of the company’s development activities may not be positive, or predictive of real-world results or of results in subsequent trials, and preliminary or interim results of the company’s development activities may not be predictive of final results of such activities, results of future preclinical or clinical trials or real-world results; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company’s products; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks, assumptions and uncertainties described

Note Regarding Trademarks: The company and its affiliates are the owners of various U.S. federal trademark registrations (®) and other trademarks (™), including ARISTADA®, ARISTADA INITIO®, and VIVITROL®. VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license. RISPERDAL CONSTA®, INVEGA SUSTENNA® and XEPLION® are registered trademarks of Johnson & Johnson (or its affiliates). FAMPYRA® is a registered trademark of Acorda Therapeutics, Inc. Any other trademarks referred to in this presentation are the property of their respective owners. Appearances of such other trademarks herein should not be construed as any indicator that their respective owners will not assert their rights thereto.
Alkermes’ Distinctive Mission and Impact

Through our advocacy, we advance patient-centered care and seek to redefine what constitutes successful treatment.

Our science and medicines are making a real-world impact in the treatment of serious diseases.
2020 Key Business Objectives

Expanding and driving growth of our **product portfolio**

Advancing a **diversified neuroscience and oncology pipeline**

Positioning the business to deliver **long-term growth** and profitability
Expanding and Driving Growth of Our Product Portfolio
Proprietary Commercial Products for Addiction and Schizophrenia

• Extended-release opioid antagonist provides therapeutic levels of naltrexone for a one-month period

• Only medication indicated for the prevention of relapse to opioid dependence, following opioid detoxification; Indicated for the treatment of alcohol dependence

• Long-acting injectable (LAI) atypical antipsychotic indicated for the treatment of schizophrenia

• First and only LAI with ability to fully dose on day one* for up to two months with ARISTADA INITIO® regimen

*ARISTADA INITIO + single 30 mg oral dose of aripiprazole replaces need for concomitant three weeks of oral aripiprazole for initiation of ARISTADA, with relevant levels of aripiprazole concentration reached within four days. The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.
$1 Billion Topline Commercial Enterprise Driven by Growth of Proprietary Products

2019 Key Elements of Revenue
- Proprietary commercial products
  - VIVITROL®
  - ARISTADA®
- Financial foundation of license, royalty and manufacturing revenues

New potential revenue elements:
2020
- Royalty and manufacturing: VUMERITY®
2021
- Proprietary psychiatry portfolio: Potential launch of ALKS 3831 (pending FDA approval)
VUMERITY® (Diroximel Fumarate) for Multiple Sclerosis (MS)

• Novel oral fumarate with a distinct chemical structure for the treatment of relapsing forms of MS
• Discovered and developed by Alkermes
• Approved by FDA in October 2019
• Biogen holds exclusive, worldwide license to develop and commercialize
  - Launched by Biogen in late Q4 2019
  - 15% royalty to Alkermes on worldwide net sales
  - Potential for additional indications and ex-U.S. opportunities
• Composition of matter patent extends into 2033

Now Approved
ALKS 3831: A Potential New Oral Treatment for Adults With Schizophrenia and Adults With Bipolar I Disorder

- Investigational antipsychotic designed to offer efficacy of olanzapine; addition of samidorphan intended to mitigate olanzapine-associated weight gain
- Single NDA for treatment of adults with schizophrenia and adults with bipolar I disorder under FDA review:
  - PDUFA target action date: Nov. 15, 2020
  - Preparing for advisory committee meeting
- Fixed-dose combination
  - Bilayer tablet of samidorphan (10 mg) and olanzapine (5 mg, 10 mg, 15 mg, or 20 mg)
ALKS 3831: Efficacy, Safety and Weight Gain Profile Observed in Phase 3 Development Program in Patients With Schizophrenia

<table>
<thead>
<tr>
<th>ENLIGHTEN-1 Efficacy Study</th>
<th>ENLIGHTEN-2 Weight Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Antipsychotic efficacy vs. placebo</td>
<td></td>
</tr>
<tr>
<td>• 403 patients with acute schizophrenia</td>
<td></td>
</tr>
<tr>
<td>• ALKS 3831 demonstrated statistically significant reductions from baseline in PANSS scores at 4 weeks, compared to placebo ( p&lt;0.001 )</td>
<td></td>
</tr>
<tr>
<td>• Olanzapine achieved similar improvements from baseline PANSS scores, compared to placebo ( p=0.004 )</td>
<td></td>
</tr>
<tr>
<td>• Weight change vs. olanzapine</td>
<td></td>
</tr>
<tr>
<td>• 561 patients with stable schizophrenia</td>
<td></td>
</tr>
<tr>
<td>• Demonstrated statistically significant improvement compared to olanzapine at 6 months for both co-primary endpoints:</td>
<td></td>
</tr>
</tbody>
</table>
  - Percent change from baseline in body weight \( p=0.003 \) |
  - Proportion of subjects with ≥10% weight gain \( p=0.003 \) |
ENLIGHTEN-1: Demonstrated Robust Antipsychotic Efficacy

<table>
<thead>
<tr>
<th>Change from Baseline at Week 4</th>
<th>PBO (N=112)</th>
<th>ALKS 3831 (N=124)</th>
<th>OLZ (N=120)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>-19.4 (14.80)</td>
<td>-23.7 (12.61)</td>
<td>-22.4 (13.63)</td>
</tr>
<tr>
<td>LS Mean (SE)</td>
<td>-17.5 (1.32)</td>
<td>-23.9 (1.28)</td>
<td>-22.8 (1.29)</td>
</tr>
<tr>
<td>LS Mean Difference (SE) vs. Placebo</td>
<td>-6.4 (1.83)</td>
<td>-5.3 (1.84)</td>
<td></td>
</tr>
<tr>
<td>P-Value</td>
<td>&lt;0.001</td>
<td>0.004</td>
<td></td>
</tr>
</tbody>
</table>

Change From Baseline in PANSS Total Score (LS Mean ± SE)

-30 -25 -20 -15 -10 -5 0
Baseline 8 15 22 29
Day

* p<0.05
** p<0.01
*** p<0.001

Treatment Group:
- Placebo
- Olanzapine
- ALKS 3831
ENLIGHTEN-2 Results

Prespecified Analysis | Olanzapine | ALKS 3831
--- | --- | ---
Co-Primary Endpoints: | | |
Mean Weight Gain | 6.59% | 4.21% |
p-value | | p=0.003 |
Proportion of Subjects with Weight Gain of ≥10% From Baseline | 29.8% | 17.8% |
p-value | | p=0.003 |
Secondary Endpoint: | | |
Proportion of Subjects with Weight Gain of ≥7% From Baseline | 42.7% | 27.5% |
p-value | | p=0.001 |

Clinical Implications for Patients

- 73% of ALKS 3831 patients did not gain clinically meaningful* weight from baseline.
- 2.0x the risk of clinically meaningful* weight gain from baseline with olanzapine vs. ALKS 3831.
- 57% higher mean percent weight change at six months for patients who received olanzapine vs. ALKS 3831.

The most common adverse events for ALKS 3831 were weight gain, somnolence and dry mouth. The most common adverse events for olanzapine were weight gain, somnolence and increased appetite.

*Using at least 7% increase from baseline body weight as the benchmark of clinical significance.
ENLIGHTEN-2: ALKS 3831 Weight Profile Stabilized

Note: Weight curve based on analysis of covariance (ANCOVA) approach using multiple imputation (MI) for missing data.

*p<0.05 vs. olanzapine; **p<0.01 vs. olanzapine
ENLIGHTEN-2: Weight Gain Trajectory of Early Discontinuations

Percent Change From Baseline in Body Weight by Treatment*
Completers vs. Premature Discontinuations

Study Week

Percent Change From Baseline in Body Weight (%) (Mean)

Olanzapine

ALKS 3831

*Solid lines denote the weight gain curve of patients who completed the study. Dashed lines denote weight gain curves of subjects who prematurely discontinued at given visits. Numbers of patients summarized in each curve are noted.
ENLIGHTEN-2-EXT Interim Results: Weight Remains Stable Over 52 Weeks

Percent Change in Body Weight From ENLIGHTEN-2-EXT Baseline

<table>
<thead>
<tr>
<th>Study Week</th>
<th>Percent Change From Baseline in Body Weight (Mean ± SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>24</td>
<td>0</td>
</tr>
<tr>
<td>28</td>
<td>0</td>
</tr>
<tr>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>44</td>
<td>0</td>
</tr>
<tr>
<td>48</td>
<td>0</td>
</tr>
<tr>
<td>52</td>
<td>0</td>
</tr>
</tbody>
</table>

Weight Remains Stable Over 52 Weeks
Alkermes’ Evolving Research and Development Capabilities

**R&D Focus**

**Capabilities**

**Approved Medicines, Drug Candidates & Therapeutic Areas**

**2000s**
- Formulation & Drug Delivery
- Modifying Existing Small Molecules, Proteins, Peptides
- LAI Atypical Antipsychotics*
  - VIVITROL®
  - BYDUREON®*

**2010s**
- New Molecular Entities
- Prodrug & NCE Chemistry, Cytokine Engineering
- ARISTADA®
  - VUMERITY®**
  - ALKS 3831
  - ALKS 4230

**2020**
- New Biology in Neuroscience & Oncology
- Small Molecule Chemistry, Protein Fusion
- Psychiatry Neurodegeneration Oncology

*Third-party products that use Alkermes proprietary technology under license.

** Licensed product.
# Building Fully-Integrated Capabilities Across Neuroscience and Oncology

<table>
<thead>
<tr>
<th></th>
<th>Neuroscience</th>
<th>Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research &amp; Discovery</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Formulation &amp; CMC</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clinical Trial Operations</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Regulatory Affairs</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Medical Affairs</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Commercial</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Patient Engagement</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

## 2020 Priorities
- Expand ex-U.S. trial network
- Evaluate strategic development and commercial partnerships
Research and Development Pipeline:
Novel Molecules in High-Potential Therapeutic Areas

<table>
<thead>
<tr>
<th>ALKS 3831</th>
<th>Schizophrenia/ Bipolar I Disorder*</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALKS 4230</td>
<td>Oncology (Intravenous Dosing)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALKS 4230</td>
<td>Oncology (Subcutaneous Dosing)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective</td>
<td>Neurodegenerative Disorders (Orphan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDAC</td>
<td>Neurodegenerative Disorders (Prevalent, Non-orphan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PDUFA target action date Nov. 15, 2020

* Neuroscience  Oncology
Research and Development Pipeline: Status and Priorities

**ALKS 3831**
- Prescription Drug User Fee Act (PDUFA) target action date: Nov. 15, 2020
- Preparing for Advisory Committee meeting anticipated in Fall 2020

**ALKS 4230**
- Patient enrollment ongoing in ARTISTRY-1 and ARTISTRY-2
- Activation of select ex-U.S. sites primarily in the Asia Pacific region and Europe expected in Q2’20

**Selective HDAC Inhibitors**
- Maintain momentum and prepare for IND-enabling activities

*COVID-19 has impacted enrollment rates and timelines of certain clinical trials; Ongoing studies continuing with appropriate precautions*
Advancing a Diversified Pipeline

ALKS 4230
ALKS 4230: Selective IL-2 Fusion Protein

• Novel investigational drug designed to leverage proven anti-tumor effects of interleukin-2 (IL-2) pathway

• Stable, single polypeptide designed to selectively bind to intermediate-affinity IL-2 receptor and expand tumor-killing CD8+ and Natural Killer (NK) T cells, and have negligible effects on T_{reg} expansion

• ARTISTRY-1 and ARTISTRY-2 phase 1/2 studies ongoing

• Data presented at Society of Immunotherapy of Cancer meeting in Nov. 2019
IL-2 Activates and Expands Immune Suppressive Regulatory T Cells That Dampen Anti-Cancer Immune Responses

Graphics for illustrative purposes only.
ALKS 4230 Designed to Selectively Activate Intermediate-Affinity Receptor

**ALKS 4230 Design Intention:**

- Preferentially expand cancer-fighting CD8\(^+\) T cells and NK cells to potentially improve anti-tumor efficacy
- Prevent IL-2-derived expansion of T\(_{reg}\) cells to minimize inhibition of immune response
- Mitigate certain side effects of IL-2, including vascular leak syndrome

(Graphics for illustrative purposes only.)
## Overview of ALKS 4230 Clinical Development Program

### ARTISTRY-1
**Phase 1/2**
- **Intravenous dosing**
  - Refractory advanced solid tumors
- **Part A**: Monotherapy dose escalation
- **Part B**: Monotherapy dose expansion
- **Part C**: ALKS 4230 + pembrolizumab combination

### ARTISTRY-2
**Phase 1/2**
- **Subcutaneous dosing**
  - Refractory advanced solid tumors
- **Part A**: Monotherapy dose escalation
- **Part B**: Monotherapy dose expansion
- **Part C**: ALKS 4230 + pembrolizumab combination
  - Evaluating once-weekly and once every three weeks dosing
- **Efficacy expansion phase planned**

### ION-01
**Phase 2**
- **Intravenous dosing**
  - Anti-PD-1 pre-treated HNSCC* patients
- **Collaboration with Fred Hutchinson Cancer Research Center**
- **ALKS 4230 + pembrolizumab combination**
- **Assessment of tumor microenvironment from paired biopsies**
- **Predictive biomarker assessments**

*HNSCC*: Head and neck squamous cell carcinoma
ALKS 4230: ARTISTRY-1 Phase 1/2 Study Design

Part A: Monotherapy Dose Escalation
   Inpatient
   Identified RP2D of 6 µg/kg
   Ongoing to determine MTD

Part B: Monotherapy Dose Expansion
   Outpatient
   Renal Cell Carcinoma Cohort
   Melanoma Cohort

Part C: ALKS 4230 + Pembrolizumab Combination Therapy
   Outpatient
   1 µg/kg combo safety run in
   3 µg/kg combo safety run in
   6 µg/kg combo cohorts
   PD-1/L1 approved tumor types (treatment naive)
   PD-1/L1 approved tumor types (pretreated)
   PD-1/L1 unapproved tumor types*
   Monotherapy rollover
   1st line melanoma
   2nd line NSCLC
   2nd line head and neck squamous cell carcinoma

RP2D: Recommended phase 2 dose
MTD: Maximum tolerated dose
NSCLC: Non-small cell lung cancer

*Includes colorectal, triple-negative breast, ovarian carcinoma, soft tissue sarcomas, and subjects with metastatic non-small cell lung cancer whose tumors express low or undetectable PD-L1
ARTISTRY-1 Part A Monotherapy Dose Escalation: Dose-Dependent, Selective Expansion of NK and CD8+ T Cells

Identified 6 µg/kg/day administered intravenously as recommended phase 2 dose (RP2D)
• 12 of 18 patients with evaluable scans had stable disease or better over the course of their treatment.

• Demonstrated side effect profile across completed cohorts consistent with cytokine therapy: Fever and chills were most common treatment-related adverse events; No capillary leak syndrome observed.
**ALKS 4230: ARTISTRY-2 Phase 1/2 Study Design**

**Phase 1: Dose Escalation**

- **Cohort 1**
  - 0.3 mg
  - SC q7D

**Cohorts**

- **SC q7D**
- **SC q21D**

**ALKS 4230**

- **Monotherapy Lead-in** (42 days)
- **Combination Therapy** (21 days)
- **Combination Therapy** (21 days)

**Pembrolizumab**

- (200 mg q21d)

**Safety Expansion**

- **ALKS 4230 + pembrolizumab**

**Determine RP2D and dosing frequency**

**Phase 2: Efficacy Expansion in Solid Tumors**

Combination ALKS 4230 + pembrolizumab (IV, 200 mg)

- **Cohorts of specific tumors TBD**

- Cohort 1 dosing of 0.3 mg was chosen as the starting dose based on predictive modeling

  q7d: Administered once weekly; q21d: Administered once every three weeks
Advancing a Diversified Pipeline

Selective HDAC Inhibitors
Synapses Play a Vital Role in Brain Function

• Synapses are the points of communication within the network of neurons that make up the brain

• Synaptic function is critical to brain development, learning and memory

• Synaptogenesis is the formation of synapses between neurons in the nervous system that occurs throughout a healthy person's lifespan
Synaptopathies Span Multiple Neurological Diseases Independent of Underlying Pathology

- Synaptic loss and dysfunction occur across a wide range of disorders and are associated with clinical symptoms\(^1\)

- Increased synaptic density and function strengthen neuronal connectivity, potentially leading to clinically relevant benefits\(^2\), independent of underlying disease pathology

<table>
<thead>
<tr>
<th>Neuropsychiatric</th>
<th>Neurodegenerative</th>
<th>Neurodevelopment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bipolar spectrum disorder</td>
<td>Frontotemporal dementia</td>
<td>Autism spectrum disorder</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Huntington’s</td>
<td>Fragile X syndrome</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>Alzheimer’s</td>
<td>Retinal</td>
</tr>
<tr>
<td></td>
<td>Parkinson’s</td>
<td>Epilepsy</td>
</tr>
</tbody>
</table>

Loss of Synapses Correlated to Cognitive Decline in Neurodegenerative Patients

- Preserved synaptic density observed in cognitively normal patients with underlying Alzheimer’s Disease pathology (CAD)

- Spine density was similar among control and CAD cases but was reduced significantly in patients with Alzheimer’s Disease (AD) that demonstrated clinical dementia

![Synapse loss tracked disease progression](image)

Synapse loss tracked disease progression:

- Control: ~25% ± *
- Mild: ~35% ± *
- Moderate: ~45% ± *
- Severe: ~55% ± *

Disease severity:

- Control: N=9
- Mild: N=9
- Moderate: N=8
- Severe: N=16

Epigenetic Control of Synaptogenesis

- Acetylation of histones increases accessibility of DNA for transcription of multiple genes associated with synaptogenesis.

- Deacetylation of histones by HDACs (histone deacetylase) causes tight coiling of DNA and closed chromatin leading to gene repression.

- Brain-penetrant HDAC inhibitors increase acetylation, driving prosynaptic gene expression and ultimately synaptogenesis.
Extensive Literature Discussing Prosynaptic Effects of HDAC Inhibitors

<table>
<thead>
<tr>
<th>Molecular</th>
<th>Structural</th>
<th>Functional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene and/or protein modification</td>
<td>Synapse formation</td>
<td>Increased long-term potentiation</td>
</tr>
</tbody>
</table>

**Molecular**

- An epigenetic blockade of cognitive functions in the neurodegenerating brain
- Crebinostat: A Novel Cognitive Enhancer that Inhibits Histone Deacetylase Activity and Modulates Chomatin-Mediated Neuroplasticity

**Structural**

- Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue
- The Class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction
- HDAC2 negatively regulates memory formation and synaptic plasticity

**Functional**

- SAHA Enhances Synaptic Function and Plasticity *In Vitro* but Has Limited Brain Availability *In Vivo* and Does Not Impact Cognition
- Modulation of long-term memory for object recognition via HDAC inhibition
- Exercise and Sodium Butyrate Transform a Subthreshold Learning Event into Long-Term Memory via a Brain-Derived Neurotrophic factor-Dependent Mechanism
New Chemistry Targets Selective HDAC Complexes

- Approved HDAC inhibitor compounds have been limited by hematological toxicities, precluding application to chronic neurologic conditions.

- HDACs function in association with multi-protein complexes which determine their activity.

- Alkermes’ proprietary compounds target specific subsets of HDAC complexes.

- CoREST (co-repressor of repressor element-1 silencing transcription factor) is directly involved in repression of prosynaptic genes in neuronal tissue.

Progress Across Three Key Areas of Optimization of HDAC Inhibitors for Synaptopathies

- **Brain Penetration**: Novel chemotypes designed to enable good brain PK and ADME properties

- **CoREST Selectivity**: Selective HDAC-CoREST modulation* activity observed

- **Toxicity**: Demonstrated significantly improved hematological safety*

PK: Pharmacokinetic; ADME: Absorption, distribution, metabolism and excretion

*Fuller et al. ACS Chem. Neurosci. 2019, 10, 1729-1743
“…novel HDAC inhibitor compounds that selectively inhibit the HDAC–co-repressor of repressor element-1 silencing transcription factor (CoREST) complex while minimizing hematological side effects…selectively targeting the CoREST co-repressor complex…results in increased spine density and synaptic proteins, and improved long-term potentiation in a mouse model at doses that provide a substantial safety margin that would enable chronic treatment.”

Advancing Preclinical Research and IND-Enabling Activities

• HDAC CoREST inhibitors for synaptopathies
  Pursue IND-enabling activities for lead preclinical compounds
  - Potential utility across highly-prevalent neurodegenerative diseases such as Alzheimer’s Disease as well as orphan diseases such as frontotemporal dementia and Huntington’s Disease

• Oncology and other disease areas
  Continue exploratory work to assess the potential utility of selective HDAC modulation

• Translational development and biomarkers
  Continue development of biomarker and translational tools to help demonstrate potential target engagement and efficacy
Positioning the Business to Deliver Long-Term Growth and Profitability
Positioning Alkermes for Long-Term Growth

- VIVITROL®, ARISTADA® & ARISTADA INITIO®: Executing commercial plans; adapting commercial strategy in response to COVID-19
- VUMERITY®: Received FDA approval; Launched by Biogen
- ALKS 3831: Submitted NDA; Preparing for advisory committee; Launch preparation activities ongoing
- ALKS 4230: expanding clinical program driven by emerging data; site expansion continuing despite COVID-19-related delays
- Acquired Rodin Therapeutics & introduced HDAC inhibitor platform
- Focusing investment in highest-potential R&D programs
- Implemented strategic restructuring to reduce cost structure
- Added expertise in oncology and strategic value creation to Board with appointment of two new Directors
Alkermes’ Response to COVID-19
Operational Priorities in Response to COVID-19

1. Protect the Well-Being of Employees
   - Remote work policy for those who can carry out responsibilities remotely
   - Virtual customer engagements for field-based personnel
   - Additional employee safety precautions in labs and manufacturing facilities

2. Business Continuity
   - Preserve ability to supply:
     - VIVITROL®, ARISTADA® & ARISTADA INITIO®
     - Third-party commercial products
     - Investigational product for ongoing clinical trials
   - Continue ongoing R&D, regulatory and commercial activities

3. Innovation
   - Find streamlined ways of working
   - Develop new best practices that may have a lasting positive impact
COVID-19 Impact and Response

Ongoing Clinical Studies
- Ongoing studies continuing with appropriate precautions
- COVID-19 has impacted enrollment rates and timelines of certain clinical trials
- Frequent communication with investigators regarding impact of current environment on conduct of clinical trials
- Focus on supporting treatment continuity and ensuring patient safety

Commercial Impact & Strategy
- Disruptions in access and demand for healthcare provider administered medicines have negatively impacted sales of VIVITROL®, and to a lesser extent, ARISTADA®
- Customer engagement strategy transitioned to a virtual model
- Goal to advance digital capabilities while continuing to support broad access to VIVITROL, ARISTADA and ARISTADA INITIO®
- Focus on supporting evolving needs of healthcare providers and patients

2020 Financial Outlook
- Cash, cash equivalents and total investments of $549.7M at March 31, 2020 provide liquidity to continue to advance company objectives
- Financial expectations* withdrawn due to uncertainties related to the impact of the COVID-19 pandemic on Alkermes’ operating and financial results for 2020

## Diverse Commercial Portfolio With Long Patent Lives*

<table>
<thead>
<tr>
<th>Description</th>
<th>Patent Life</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vivitrol</strong></td>
<td></td>
</tr>
<tr>
<td>Once-monthly medication for treatment</td>
<td>2029 in U.S.**</td>
</tr>
<tr>
<td>of alcohol and opioid dependence</td>
<td></td>
</tr>
<tr>
<td><strong>Aristada</strong></td>
<td></td>
</tr>
<tr>
<td>Long-acting atypical antipsychotic</td>
<td>2035 in U.S.</td>
</tr>
<tr>
<td>for treatment of schizophrenia with once-monthly, six-week and two-month</td>
<td></td>
</tr>
<tr>
<td>dosing</td>
<td></td>
</tr>
<tr>
<td><strong>Risperdal Consta</strong> †</td>
<td></td>
</tr>
<tr>
<td>(A Janssen product)</td>
<td>2023 in U.S.</td>
</tr>
<tr>
<td>Long-acting atypical antipsychotic</td>
<td>2021 in EU</td>
</tr>
<tr>
<td>for treatment of schizophrenia and bipolar I disorder</td>
<td></td>
</tr>
<tr>
<td>**Invega Sustenna® / Xeplion® †</td>
<td></td>
</tr>
<tr>
<td>(Janssen products)</td>
<td>2031 in U.S.</td>
</tr>
<tr>
<td>Long-acting atypical antipsychotic</td>
<td>2022 in EU</td>
</tr>
<tr>
<td>for treatment of schizophrenia and schizoaffective disorder</td>
<td></td>
</tr>
<tr>
<td>**Fampyra® ‡</td>
<td></td>
</tr>
<tr>
<td>(An Acorda product)</td>
<td>2025 in EU</td>
</tr>
<tr>
<td>Treatment to improve walking in patients</td>
<td></td>
</tr>
<tr>
<td>with multiple sclerosis</td>
<td></td>
</tr>
<tr>
<td><strong>Vumerity</strong> †</td>
<td></td>
</tr>
<tr>
<td>(dinoprostone fumarate)</td>
<td>2033 in U.S.</td>
</tr>
<tr>
<td>Novel oral fumarate for the treatment of relapsing forms of MS</td>
<td>2034 in EU</td>
</tr>
</tbody>
</table>

* Please refer to the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2019 for details of the expected duration of royalties for each product, which may differ from the patent life set forth above.

** Pursuant to a settlement agreement, Amneal Pharmaceuticals LLC holds a non-exclusive right to market a generic formulation of Vivitrol in the U.S. beginning sometime in 2028 or earlier under certain circumstances.

*** Vumerity is commercialized by Biogen pursuant to an exclusive license and collaboration agreement.

† Risperdal Consta®, Invega Sustenna®, and Xeplion® are Johnson & Johnson products that incorporate Alkermes proprietary technology under license and are commercialized by Janssen Pharmaceuticals Inc.

‡ Fampyra® is a product of Acorda Therapeutics, Inc. (Acorda). Fampyra® is being developed and marketed outside the U.S. by Biogen, under a licensing agreement with Acorda.
Patent Protection for Pipeline Candidates Extends Into Next Decade and Beyond

<table>
<thead>
<tr>
<th>Description</th>
<th>Patent Life (U.S.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALKS 3831</strong></td>
<td></td>
</tr>
<tr>
<td>Investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder</td>
<td>2032</td>
</tr>
<tr>
<td>Novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex</td>
<td>2033</td>
</tr>
<tr>
<td><strong>ALKS 4230</strong></td>
<td></td>
</tr>
</tbody>
</table>